Polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Control group: Placebo tablet, daily, for 8 weeks orally. Intervention 2: Intervention group: Selenium tablet, 200 µg, daily, for 8 weeks orally.
Sponsors
Ardabil University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
18 Years to 40 Years
Inclusion criteria
Inclusion criteria: Women aged 18-40 years Diagnosed with PCOS
Exclusion criteria
Exclusion criteria: Elevated levels of prolactin Thyroid disorder T2DM Congenital adrenal hyperplasia Had normal baseline renal function tests, bilirubin, and aminotransferases During the last 3 months before the intervention used anyform of oral contraceptives (OCPs), steroid hormones, or any other treatments likely to affect ovarian function, insulin sensitivity, or inflammatory factors, biomarkers of oxidative stress.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Malondialdehyde. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;FSH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;LH. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa.;Free testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Hs-CRP. Timepoint: Baseline and End-of-trial. Method of measurement: Elisa kit.;Total antioxidant. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry.;Nitric oxide. Timepoint: Baseline and End-of-trial. Method of measurement: Spectrophotometry. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZatollah Asemi
Kashan University of Medical Sciences
Outcome results
None listed